The utilization of MRD in ALL is evolving rapidly, with certain centers routinely testing for MRD, particularly in the pediatric setting1,2.

MRD has proven to be a key determinant of likely treatment failure or response in ALL1-3. The optimal outcome from the use of novel agents is the production of deep responses, which require sensitive measures to detect. MRD could potentially provide this; allowing the identification of efficacious agents in trials4,5.

  1. van Dongen JJ, van der Velden VH, Brüggemann M, et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015 Jun 25; 125(26): 3996-4009.
  2. VJHemOnc (2018). Minimal residual disease: a key determinant of ALL treatment response. Available at: https://www.vjhemonc.com/video/3n-t2maeci4-minimal-residual-disease-a-key-determinant-of-all-treatment-response (Accessed: 03 July 2018).
  3. Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018 Apr 5; 131(14): 1522-1531.
  4. VJHemOnc (2018). The importance of MRD assessment in all phases of ALL treatment. Available at: https://www.vjhemonc.com/video/8uayqmsw6zu-the-importance-of-mrd-assessment-in-all-phases-of-all-treatment (Accessed: 03 July 2018).
  5. Brüggemann M, Kotrova M. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Blood Adv. 2017 Nov 28; 1(25): 2456-2466.
View overview page

MRD and Acute Lymphoblastic Leukemia

MRD content on VJHemOnc.com is sponsored by AbbVie Ltd and Adaptive Biotechnologies. The companies have no influence over the production of the content

MRD and Acute Lymphoblastic Leukemia

The utilization of MRD in ALL is evolving rapidly, with certain centers routinely testing for MRD, particularly in the pediatric setting1,2.

MRD has proven to be a key determinant of likely treatment failure or response in ALL1-3. The optimal outcome from the use of novel agents is the production of deep responses, which require sensitive measures to detect. MRD could potentially provide this; allowing the identification of efficacious agents in trials4,5.

  1. van Dongen JJ, van der Velden VH, Brüggemann M, et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015 Jun 25; 125(26): 3996-4009.
  2. VJHemOnc (2018). Minimal residual disease: a key determinant of ALL treatment response. Available at: https://www.vjhemonc.com/video/3n-t2maeci4-minimal-residual-disease-a-key-determinant-of-all-treatment-response (Accessed: 03 July 2018).
  3. Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018 Apr 5; 131(14): 1522-1531.
  4. VJHemOnc (2018). The importance of MRD assessment in all phases of ALL treatment. Available at: https://www.vjhemonc.com/video/8uayqmsw6zu-the-importance-of-mrd-assessment-in-all-phases-of-all-treatment (Accessed: 03 July 2018).
  5. Brüggemann M, Kotrova M. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Blood Adv. 2017 Nov 28; 1(25): 2456-2466.
View overview page
MRD content on VJHemOnc.com is sponsored by AbbVie Ltd and Adaptive Biotechnologies. The companies have no influence over the production of the content